

Amgen Inc.**Reconciliations of GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share****(Unaudited)**

The table below shows Amgen's U.S. generally accepted accounting principles (GAAP) diluted earnings per share reconciliations to adjusted diluted earnings per share (a non-GAAP financial measure) for the years ended December 31, 2015, 2014, 2013, 2012 and 2011.

	Year ended December 31, 2015	Year ended December 31, 2014	Year ended December 31, 2013	Year ended December 31, 2012	Year ended December 31, 2011
GAAP earnings per share (diluted)	\$ 9.06	\$ 6.70	\$ 6.64	\$ 5.52	\$ 4.04
Adjustments to GAAP earnings per share (a):					
Acquisition-related expenses (b)	1.21	1.34	0.91	0.42	0.24
Certain charges pursuant to our restructuring and other cost savings initiatives (c)	0.11	0.52	0.06	0.31	0.12
Expense related to various legal proceedings	0.10	-	0.02	0.07	0.78
Expense resulting from clarified guidance on branded prescription drug fee (d)	-	0.17	-	-	-
Non-cash interest expense associated with our convertible notes	-	-	0.01	0.11	0.10
Stock option expense	-	-	-	0.05	0.06
Other tax adjustments (e)	(0.10)	(0.03)	(0.04)	0.03	(0.01)
Adjusted earnings per share (diluted)	<u>\$ 10.38</u>	<u>\$ 8.70</u>	<u>\$ 7.60</u>	<u>\$ 6.51</u>	<u>\$ 5.33</u>

- (a) The above adjustments are presented net of their related per-share tax impact of \$0.65, \$0.93, \$0.49, \$0.42 and \$0.38 for the years ended December 31, 2015, 2014, 2013, 2012 and 2011, respectively.
- (b) To exclude expenses related primarily to non-cash amortization of intangible assets, including developed product technology rights, acquired in business combinations.
- (c) To exclude expenses related primarily to severance, accelerated depreciation and other charges related to the closure of our facilities. 2015 also included gains recognized on the sale of assets related to our site closures.
- (d) To exclude the expense related to the recognition of an additional year of the non-tax deductible branded prescription drug fee, as required by final regulations issued by the Internal Revenue Service.
- (e) To exclude the impacts related to certain prior period items excluded from adjusted earnings, as well as resolving certain non-routine transfer-pricing and acquisition-related issues with tax authorities, as applicable.